{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    7,
    15,
    35,
    36,
    39,
    40,
    43
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Schedule of Activities Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference from Section 9 to the Schedule of Activities for timing of study procedures."
      },
      {
        "id": "ref_2",
        "name": "Clinical Laboratory Tests Appendix Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 2",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference from Section 9 to Appendix 2 for a list of laboratory tests to be performed."
      },
      {
        "id": "ref_3",
        "name": "Blood Sampling Summary Appendix Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 5",
        "sectionTitle": "Blood Sampling Summary",
        "description": "Reference from Section 9 to Appendix 5 for a summary of the maximum number and volume of invasive samples."
      },
      {
        "id": "ref_4",
        "name": "Edinburgh Hypoglycemia Scale Appendix Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 7",
        "sectionTitle": "Edinburgh Hypoglycemia Scale",
        "description": "Reference from Section 9.1.3 to Appendix 7 for the self-reported assessment tool for hypoglycemia symptoms."
      },
      {
        "id": "ref_5",
        "name": "Clarke Hypoglycemia Awareness Survey Appendix Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 8",
        "sectionTitle": "Clarke Hypoglycemia Awareness Survey",
        "description": "Reference from Section 9.1.3 to Appendix 8 for the self-report assessment of hypoglycemic symptom identification."
      },
      {
        "id": "ref_6",
        "name": "Treatment Details Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7",
        "sectionTitle": "Treatment",
        "description": "Reference from Section 9.2.2 to Section 7 for details regarding treatments."
      },
      {
        "id": "ref_7",
        "name": "Nasal and Non-nasal Score Questionnaire Appendix Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 6",
        "sectionTitle": "Nasal and Non-nasal Score Questionnaire",
        "description": "Reference from Section 9.2.2.1 to Appendix 6 for the questionnaire to document sneezing after administration."
      },
      {
        "id": "ref_8",
        "name": "Hepatic Monitoring Tests Appendix Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 4",
        "sectionTitle": "Hepatic Monitoring Tests for Treatment-emergent Abnormality",
        "description": "Reference from Section 9.5.5.2 to Appendix 4 for liver tests to be repeated in case of abnormalities."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release. In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Title Page",
        "pageNumber": 2
      },
      {
        "id": "annot_2",
        "text": "At Periods 1 and 2, samples should be collected from patients who have fasted at least 8 hours before any study procedures.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 16
      },
      {
        "id": "annot_3",
        "text": "Patients do not need to fast for samples at screening or follow-up.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 16
      },
      {
        "id": "annot_4",
        "text": "If an SAE occurs after signing informed consent, but prior to receiving investigational product, AND is considered reasonably possibly related to a study procedure then it MUST be reported.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.3.1 Serious Adverse Events",
        "pageNumber": 40
      },
      {
        "id": "annot_5",
        "text": "Only SAEs elicited through the Nasal and Non-nasal Score Questionnaire and Edinburgh Hypoglycemia Scale are to be recorded as AEs via CRF and reported to Lilly or its designee within 24 hours as SAEs.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.3.1.2 Adverse Event Monitoring with a Systematic Questionnaire",
        "pageNumber": 40
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "I8R-JE-IGBJ(a)",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-12-05",
        "description": "Protocol Amendment (a) to Phase 3 Study I8R-JE-IGBJ. Initial protocol approval on 2017-10-26, amendment approval on 2017-12-05.",
        "amendmentNumber": "a"
      }
    ],
    "summary": {
      "referenceCount": 8,
      "annotationCount": 5,
      "versionCount": 1
    }
  }
}